DexCom (DXCM) to Release Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) is anticipated to announce its earnings results after the market closes on Thursday, February 13th. Analysts expect the company to announce earnings of $0.50 per share and revenue of $1.10 billion for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

DexCom Stock Up 0.2 %

Shares of NASDAQ DXCM opened at $88.27 on Tuesday. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a market cap of $34.48 billion, a PE ratio of 52.86, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. The company has a 50 day simple moving average of $81.76 and a 200 day simple moving average of $75.11.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock valued at $3,628,069 over the last ninety days. 0.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on DXCM shares. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Raymond James cut their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Canaccord Genuity Group increased their price target on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Oppenheimer decreased their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.